论文部分内容阅读
目的探讨紫杉醇(PTX)腹腔灌注治疗卵巢癌的临床疗效及安全性。方法选取2007年9月至2011年4月收治的84例卵巢癌患者,随机分为观察组和对照组,每组各42例。观察组患者采用PTX联合顺铂(PDD)腹腔灌注化疗,对照组患者采用PTX联合PDD静脉化疗,比较两组患者的疗效和不良反应情况。结果观察组患者治疗有效率为73.8%,对照组为57.1%,观察组治疗效果明显优于对照组。观察组腹部不适出现率及肾功能损伤出现率均明显低于对照组,两组患者肝功能损伤、白细胞下降及周围神经损伤发生率差异无统计学意义(P<0.05)。观察组患者1年生存率为97.6%,中位疾病进展时间(TTP)为(27.6±5.5)个月;对照组患者1年生存率为92.9%,TTP为(22.5±4.2)个月。观察组患者1年生存率及TTP均明显优于对照组。结论紫杉醇腹腔灌注治疗卵巢癌较静脉注射化疗方式具有良好的疗效及安全性,可有效保证患者的生存率及生活质量,治疗时联合顺铂可达到更好效果,值得临床推广。
Objective To investigate the clinical efficacy and safety of paclitaxel (PTX) peritoneal perfusion in the treatment of ovarian cancer. Methods Eighty-four patients with ovarian cancer who were admitted from September 2007 to April 2011 were randomly divided into observation group and control group, with 42 cases in each group. Patients in the observation group were treated with intraperitoneal infusion of PTX combined with cisplatin (PDD), while patients in the control group were treated with PTX combined with PDD. The curative effect and adverse reactions of the two groups were compared. Results In the observation group, the effective rate of treatment was 73.8% and that of the control group was 57.1%. The treatment effect of the observation group was significantly better than that of the control group. The occurrence rate of abdominal discomfort and the incidence of renal dysfunction in the observation group were significantly lower than those in the control group. There was no significant difference in the incidence of hepatic injury, leukopenia and peripheral nerve injury between the two groups (P <0.05). The one-year survival rate was 97.6% in the observation group and the median time to progression of disease (TTP) was (27.6 ± 5.5) months. The 1-year survival rate was 92.9% in the control group and (22.5 ± 4.2) months in the control group. The 1-year survival rate and TTP in the observation group were significantly better than those in the control group. Conclusion Intraperitoneal paclitaxel treatment of ovarian cancer than intravenous chemotherapy has good efficacy and safety, which can effectively ensure the survival rate and quality of life of patients with combined cisplatin can achieve better results, worthy of clinical promotion.